XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, representing a turnover rate of 0.03% and a price fluctuation amplitude of 3.79%. Financial reports indicate that XOMA achieved a revenue of $11.09 million, net profit of $15.99 million, and earnings per share of $0.88. The gross profit stood at $11.08 million, with a price-to-earnings ratio of -11.85. Within the indust ...

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cu ...

Core Insights - XOMA Royalty Corporation will participate in two upcoming investor conferences in September 2024, presenting corporate overviews at both events [1][2]. Group 1: Upcoming Conferences - XOMA will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York, with a presentation scheduled for September 9 at 9:00 AM ET [1]. - The company will also present at the 2024 Cantor Global Healthcare Conference from September 17-19, 2024, in New York, with a presentation on September 17 at 2:30 PM ET [1]. Group 2: Access to Presentations - Presentations can be accessed via the investor relations section of XOMA's website, and replays will be available for 90 days post-event [2]. Group 3: Company Overview - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical or biotech companies [3]. - The company provides non-dilutive, non-recourse funding to sellers, enabling them to advance their drug candidates or for general corporate purposes [3]. - XOMA has a growing portfolio of assets, defined as rights to receive potential future economics from therapeutic candidates [3].

XOMA Royalty (XOMA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -7.69%. A quarter ago, it was expected that this drug developer would post a loss of $0.71 per share when it actually produced a loss of $0.86, delivering a surprise of -21.13%. Over the last four quarters, the company has n ...

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Key Second Quarter Events Partner Event The U.S. Food and Drug Administration (FDA) approved Day One's OJEMDA™ (tovorafenib) for use in patients with pediatric low-grade glioma (pLGG). XOMA Royalty earned a $9.0 million milestone upon the approval and recorded $0.4 million in income resulting from OJEMDA™ sales in the second quarter of 2024. In addition, XOMA Royalty received an ...

Exhibit 99.1 XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities "We continue to build the foundation for accelerating value creation with a disciplined approach to capital deployment," stated Owen Hughes, Chief Executive Officer of XOMA. "In recent months, we've completed the acquisition of Kinnate, acquired economic interests in two commercial assets, as well as in two first-in-class Phase 3 assets, and initiated our first share buyback program on the heels of securing the V ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________to__________ Commission File Number: 001-39801 XOMA Corporation (Exact name of Registrant as specified in its charter) Delaware 52-2154066 (State or other ju ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39801 XOMA CORPORATION (Exact name of Registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdictio ...

Revenue and Financial Performance - XOMA reported total revenues of $1.8 million for Q4 2023 and $4.8 million for the full year, down from $6.0 million in 2022[5]. - The company recognized $2.5 million in milestone payments from two partners in 2023, compared to $4.0 million from four partners in 2022[5]. - XOMA received approximately $5.7 million in cash payments from royalties and milestone payments in Q4 2023, up from $0.8 million in Q4 2022[8]. - Net loss for 2023 was $40.8 million, worsening from a net loss of $17.1 million in 2022[26]. - The net loss for Q4 2023 was $20.1 million, compared to a net loss of $6.0 million in Q4 2022[11]. - Cash flows from operating activities showed a net cash used of $18.2 million in 2023, compared to $12.9 million in 2022[26]. Expenses and Liabilities - General and administrative expenses were $7.3 million for Q4 2023 and $25.6 million for the full year, an increase of $2.4 million from 2022 primarily due to higher stock-based compensation[6]. - The company incurred $15.8 million in impairment charges in 2023 due to the discontinuation of operations at Bioasis and the termination of the License Agreement for ebopiprant[9]. - Current liabilities rose significantly to $19.5 million in 2023, compared to $6.8 million in 2022, an increase of 186%[24]. - Total liabilities surged to $145.6 million in 2023, compared to $16.4 million in 2022, reflecting a dramatic increase of 786%[24]. - Payments of consideration under RPAs, AAAs, and CPPAs amounted to $14.7 million in 2023, up from $8.0 million in 2022[26]. - The company reported stock-based compensation expense of $9.1 million in 2023, compared to $3.6 million in 2022, an increase of 153%[26]. Assets and Equity - As of December 31, 2023, XOMA had cash and cash equivalents of $159.6 million, significantly up from $57.8 million at the end of 2022[12]. - Cash and cash equivalents at the end of 2023 were $159.6 million, a substantial increase from $57.8 million at the end of 2022, marking a growth of 176%[26]. - Total assets increased to $234.3 million in 2023, up from $140.4 million in 2022, representing a growth of 67%[24]. - Stockholders' equity decreased to $88.7 million in 2023 from $124.0 million in 2022, a decline of 29%[24]. Financing Activities - XOMA raised up to $140 million through a royalty-backed loan related to VABYSMO® in Q4 2023[1]. - The company raised $130 million through long-term debt issuance in 2023, significantly impacting financing activities[26]. - The company plans to acquire an economic interest in DSUVIA® for $8 million, which will provide 100% of royalties until $20 million is reached[15]. Future Outlook - XOMA anticipates FDA action dates for tovorafenib and arimoclomol NDAs on April 30, 2024, and September 21, 2024, respectively[4].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________to__________ Commission File No. 001-39801 XOMA Corporation (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other ju ...